OQRO

Daily notes / October 15, 2026

Regeneron Pharmaceuticals (REGN) on October 15, 2026: 27 filings in one day

By OQRO's software, from the records of . Published . 2 min read.

Black-and-white street view of the New York Stock Exchange, with its columns and sculpted pediment beside the Wilks Building and the edge of the statue of George Washington at the right.
The New York Stock Exchange and the Wilks Building, about 1921. Photo: Irving Underhill, Public domain (Library of Congress: no known restrictions on publication). Original

The short answer

On October 15, 2026, 27 filings about Regeneron Pharmaceuticals (REGN) entered OQRO's records: 27 insider sales. That made it one of the busiest listed companies of the day. Each line below links to the filing as it was made with the SEC, the House, the Senate or USAspending.

What was filed about Regeneron Pharmaceuticals on October 15, 2026?

27 filings about Regeneron Pharmaceuticals carried the date October 15, 2026 in OQRO's records: 27 insider sales. It was one of the busiest companies of the day by number of filings.

Which filings?

  • Officer sold ~$361K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$354K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$296K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$292K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$218K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$214K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$207K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$173K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$167K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$163K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$147K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$98K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$94K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$81K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing
  • Officer sold ~$56K of REGN shares in the open market (Andrew J Murphy, Co-Chief Scientific Officer), dated Oct 14, 2026: the filing

What this does not tell you

Several filings on one day usually share a cause that the filings do not state: a 13F deadline, a trading window after results, a grant date. The Regeneron Pharmaceuticals page shows every filing with its source, the price next to it and a dated summary of the last 12 months. This page lists what was filed on one day, with each record linked to its source. A filing does not say why it was made, and this is not investment advice.

Sources

No language model wrote this page: every figure is one of the day's records, linked to its filing. It describes what was filed, not why, and it is not investment advice. How OQRO treats data

Explore the data

More daily notes